Haloperidol for the Treatment of Nausea and Vomiting in the ED
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Single center, double-blind, randomized, controlled trial in patients who present to the
emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300
patients age 18-55 presenting to the emergency department with chief complaint of nausea or
vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and
symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by
telephone at 24 hours.